Onconetix Balance Sheet Health
Financial Health criteria checks 2/6
Onconetix has a total shareholder equity of $-28.7M and total debt of $15.1M, which brings its debt-to-equity ratio to -52.6%. Its total assets and total liabilities are $59.5M and $88.2M respectively.
Key information
-52.6%
Debt to equity ratio
US$15.10m
Debt
| Interest coverage ratio | n/a |
| Cash | US$930.54k |
| Equity | -US$28.73m |
| Total liabilities | US$88.19m |
| Total assets | US$59.46m |
Recent financial health updates
Recent updates
Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation
Jan 24
Blue Water plans to evaluate BWV-201 vaccine for pneumococcal pneumonia
Oct 11Blue Water Vaccines stock jumps ~22% premarket on plans to develop monkeypox shot
Aug 17Blue Water Vaccines in pact to study Alzheimer’s vaccine
Jul 20Blue Water Vaccines: Estimates And Expectations
May 17Financial Position Analysis
Short Term Liabilities: ONCO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ONCO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ONCO has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ONCO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ONCO has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ONCO is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.